Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.63 USD | +0.30% | -1.59% | -15.54% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 241M | Capitalization | 715M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | 3M | EV / Sales 2024 * | 2.39 x |
Net cash position 2024 * | 364M | Net cash position 2025 * | - | EV / Sales 2025 * | 2.96 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-154
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | +0.24% | ||
1 week | -1.63% | ||
Current month | -21.17% | ||
1 month | -19.53% | ||
3 months | -20.84% | ||
6 months | +42.66% | ||
Current year | -15.57% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 19-08-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James F. Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 26.63 | +0.30% | 296 534 |
24-04-26 | 26.55 | +1.45% | 275,687 |
24-04-25 | 26.17 | -3.00% | 526,939 |
24-04-24 | 26.98 | -3.40% | 266,354 |
24-04-23 | 27.93 | +3.22% | 314,125 |
Delayed Quote Nasdaq, April 29, 2024 at 03:04 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.57% | 715M | |
+1.54% | 42.75B | |
+47.70% | 41.61B | |
+11.75% | 41.34B | |
-8.83% | 26.59B | |
+6.41% | 25.49B | |
-23.28% | 18.12B | |
+29.92% | 12.24B | |
-2.58% | 11.76B | |
+8.17% | 11B |
- Stock Market
- Equities
- ARCT Stock